Rancinamycins are secondary metabolites produced by Streptomyces lincolnensis in a sulfur-depleted culture medium. The structures (except stereochemistry) of the main components of the rancinamycin-complex were determined by the use of IR, UV, PMR and CMR spectra.
8 %, respectively). It was felt that the structures of the two major components could be determined from spectral data on the rancinamycin I mixture and its 2,4-dinitrophenylhydrazone** as the small amounts of the minor components would not contribute significantly to spectral data. Consequently, the following discussion is concerned only with discussion of spectral properties as they lead to the elucidation of the structures of rancinamycins la (1) and Ib (2) . Table   2 ) support this conclusion.
Two of the oxygens of rancinamycins la and Ib are present as ester groups. Absorptions in the saturated carbon region in the CMR spectrum of rancinamycin I (Table 3) combined with the presence of two ester carbonyl absorptions at 8 172.9 and 8 175.1 indicate the presence of >CH--CH2- On the basis of retention times of their trimethylsilyl derivatives", rancinamycin la is considered to contain the isobutyrate moiety while rancinamycin lb is the isomeric n-butyrate ester3. 4 The mass spectra of the TMS derivatives of rancinamycins la and lb show the presence of a strong mass ion peak at mle 372 (M+-88). This peak is due to the loss of the butyric acids from the rancinamycins la or Ib, respectively'). IR absorption at 1735 cm -1 and PMR data ( (Table 3) indicate the presence of four -CHO-groups. Three of these groups are present as -CHOH (63.50,3.75, 4.40; 1 H each) ( Table 2) (Table 3 ) and vinyl proton absorption at 8 6.96 (1 H, d) in the PMR spectrum of rancinamycin I confirm this conclusion thereby indicating the presence of fragment 3 in rancinamycins la and Ib. The physical properties of rancinamycin I-2,4-DNPH') and PMR (Table 4 ; Fig. 2 ) and CMR ( Table  5 ) spectra indicate that rancinamycin I-2,4-DNPH is a mixture of two isomeric compounds corresponding to rancinamycins la and Ib-2,4-DNPH (6 and 7 respectively).
IR absorptions at 1600, 840 and 762 cm 1,1) UV maximum at 370 nm and the aromatic or unsaturated proton and carbon absorptions in the PMR and CMR spectra (Tables 4, 5 ; Fig. 3 ) support the presence of the chromophoric system 8 in rancinamycin I-2,4-DNPH.
The presence of three hydroxyls in rancinamycin I-2,4-DNPH is supported by IR (3410, 1331, 1313, >CHOH (H-3, 6 and 7)
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H>C=C< (H-6 , 6 and 7) Absorptions in the saturated-carbon region in the CMR spectrum ( The M+-102 ion present in the mass spectra of rancinamycins II-TMS is attributed to the loss of pentanoic acid from their molecules') in contrast to the loss of butyric acid in the case of rancinamycins Ia-TMS and Ib-TMS.
IR spectra of rancinamycin 11 and rancinamycin 11-2,4-DNPH are similar to those of rancinamycin I and rancinamycin I-2,4-DNPH". In addition rancinamycin II and rancinamycin II-2,4-DNPH have UV maxima" expected for compounds containing an a,/3-unsaturated aldehyde system. The PMR spectrum of rancinamycin II-2,4-DNPH is identical to that of rancinamycin I-2,4-DNPH in all but the region from S 0.5 to 2.5 (9H)1). These results indicate that the structure of rancinamycin II-2,4-DNPH is represented by 10. The mass spectroscopic analysis described above in conjunction with data discussed earlier suggest that the structure of rancinamycins IIa to lie is represented by 11. 0 0 The PMR spectrum of rancinamycin II indicates the presence of -C-CH2CH2CH2CH3 and-C-O CH2CH-CH3 or -C-CH-CH2CH3 systems in rancinamycins 11. Thus it appears that differences in the CH3 CH3
acyl group or in stereo-chemistry account for the various rancinamycins II although there is no evidence suggesting stereochemical differences at C-2, C-3, C-4 or C-5.
Rancinamycin III
High resolution mass spectra of rancinamycin III-TMS derivative showed molecular formula of and II. These data support structure 12 for rancinamycin III.
Gas chromatographic-mass spectroscopic analysis of the trimethylsilyl-derivative of rancinamycin III indicated the presence of four isomeric components in rancinamycin III. The TMS-derivatives of all four components, designated rancinamycins IIIa, IIIb, IIIc and Illd (Table 1) , had identical molecular weight (462) and fragmentation pattern. The differences between the isomeric rancinamycins Ilia-111d, unknown at present, are probably due to differences in stereochemistry.
As in the case of rancinamycins I and II the stereochemistry at C-2, C-3, C-4 and C-5 of 12 is not known.
Rancinamycin IV
High resolution mass spectroscopy indicated the mol. formula of C,H603 for rancinamycin IV'). These data suggest that rancinamycin IV is a dihydroxybenzaldehyde.
Comparison of PMR spectral') of 3,4-dihydroxybenzaldehyde (13) and rancinamycin IV indicated that the two compounds are identical.
Biosynthetic Considerations
Pronounced structural similarities between rancinamycins I, II and III and shikimic acid (14) suggest that rancinamycins I, II and III (15) have a biogenetic origin similar to shikimic acid.
We have reported') that S. lincolnensis, when grown in a complex medium produces lincomycin only. WITz et al." have shown that tyrosine is a precursor of 4-n-propylhygric acid, the amino acid Reduction and hydroxylation of shikimic acid (A, Scheme 1) would give rancinamycin 1I1 (B) which can afford rancinamycins I and II (by acylation) or rancinamycin IV (by dehydration).
In view of the close structural relationship between shikimic acid and rancinamycins 1, II and III it is reasonable to assume that the chirality of C-3, C-4 and C-5 in the rancinamycins remains the same as it does in shikimic acid.
In the conversion of A to B, it is possible that hydroxylation could occur at C-2 or at C-6 of shikimic acid thus giving rise to four possible isomers of rancinamycin 111. The problem of stereochemistry at the asymmetric centers including absolute stereochemistry is a subject currently under consideration.
